TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12032037

Group type: EXPERIMENTAL
Intervention: Continuous psoas compartment block (CPCB) with 0.2% ropivacaine, initial loading dose of 0.4 mL/kg, followed by continuous infusion for 48 hours.
Number of subjects: 80
Study: 10221186

Group type: EXPERIMENTAL
Intervention: 1% preservative-free lidocaine intracameral injection
Number of subjects: 2

Group type: COMPARATOR
Intervention: 2% lidocaine peribulbar anesthesia
Number of subjects: 2
Study: 8750418

Group type: EXPERIMENTAL
Intervention: Prior encoding of target sounds with associated names
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior exposure to names alone (without environmental sounds)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Semantic encoding of sounds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Depth of encoding manipulations
Number of subjects: 0
Study: 2170516

Group type: EXPERIMENTAL
Intervention: Active treatment (hydrochlorothiazide 25-50 mg/day plus triamterene 50-100 mg/day, with alpha-methyldopa 0.5-2.0 g/day in one-third of patients)
Number of subjects: 822

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study: 429218

Group type: EXPERIMENTAL
Intervention: Inhalation with 95% O2 and 5% CO2
Number of subjects: 55

Group type: COMPARATOR
Intervention: Intravenous infusion with papaverin and dextran
Number of subjects: 55
Study: 31601162

Group type: EXPERIMENTAL
Intervention: Community-level intervention (CLI)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Individual-level intervention (ILI) + Community-level intervention (CLI)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Standard-of-care control
Number of subjects: 119
Study: 31801937

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 27686182

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (0.5 mL IM)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 204
Study: 25965782

Group type: EXPERIMENTAL
Intervention: Oncologist's exercise recommendation with exercise motivation package
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Oncologist's exercise recommendation
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control
Number of subjects: 162
Study: 23044702

Group type: EXPERIMENTAL
Intervention: Eccentric strengthening
Number of subjects: 32

Group type: COMPARATOR
Intervention: Concentric strengthening
Number of subjects: 32
Study: 21216000

Group type: EXPERIMENTAL
Intervention: Male circumcision (intervention group)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Control group (circumcision after 24 months)
Number of subjects: 1245
Study: 19681777

Group type: EXPERIMENTAL
Intervention: Acustimulation (active ReliefBand device at P6 acupoint)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Sham group (inactive device)
Number of subjects: 200
Study: 18054750

Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 6414

Group type: EXPERIMENTAL
Intervention: Doubling the PPI dose
Number of subjects: 6414

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 6414

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 6414

Group type: COMPARATOR
Intervention: Histamine‐2 receptor antagonists (H2RAs)
Number of subjects: 6414

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 6414

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 6414
Study: 16421072

Group type: EXPERIMENTAL
Intervention: M3S-based head-controlled wheelchair system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Head-controlled wheelchair system without M3S standard
Number of subjects: 10
Study: 12201616

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Tolterodine ER 2 mg
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Oxybutynin ER 5 mg
Number of subjects: 1289

Group type: EXPERIMENTAL
Intervention: Oxybutynin ER 10 mg
Number of subjects: 1289
Study: 9651262

Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Feedback of trial results
Number of subjects: 24
Study: 8608057

Group type: EXPERIMENTAL
Intervention: Quality of life measurement tools
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase III randomized controlled trials
Number of subjects: 0
Study: 2231756

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 479006

Group type: EXPERIMENTAL
Intervention: Indomethacin (25 mg three times a day for three days preoperatively and three weeks postoperatively)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (identical schedule to indomethacin group)
Number of subjects: 42
Study: 31156083

Group type: EXPERIMENTAL
Intervention: Extended course (EC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, tapering from 60 mg/m2 on alternate days for weeks 5-16 (total 3150 mg/m2)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard course (SC) prednisolone therapy: 60 mg/m2/day for weeks 1-4, 40 mg/m2 on alternate days for weeks 5-8, and matching placebo for weeks 9-18 (total 2240 mg/m2)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Extended course (EC) prednisolone therapy
Number of subjects: 237

Group type: COMPARATOR
Intervention: Standard course (SC) prednisolone therapy
Number of subjects: 237
Study: 29936923

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 μg/d as Se yeast)
Number of subjects: 53
Study: 27160610

Group type: EXPERIMENTAL
Intervention: Conventional method
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Wrist pivot method
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Extraoral method
Number of subjects: 90
Study: 25346332

Group type: EXPERIMENTAL
Intervention: Cold Infusions (CI) at 4°C, 2L at 4L/h
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasopharyngeal Cooling (NPC) at 60L/min for 1 h
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cold Infusions (CI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nasopharyngeal Cooling (NPC)
Number of subjects: 20
Study: 22678327

Group type: EXPERIMENTAL
Intervention: HES+E
Number of subjects: 49

Group type: COMPARATOR
Intervention: NS+E
Number of subjects: 49
Study: 21036445

Group type: EXPERIMENTAL
Intervention: Employer Perspective Scale (EPS) administered to employers regarding hiring people with health conditions
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stigma measures including attributions about disease onset and offset
Number of subjects: 100

Group type: COMPARATOR
Intervention: Employer perspectives in Chicago
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Recognition of benefits of hiring people with health conditions
Number of subjects: 100
Study: 17429183

Group type: EXPERIMENTAL
Intervention: Health literacy program workshop led by a dentist
Number of subjects: 63
Study: 15705374

Group type: EXPERIMENTAL
Intervention: Oral L-carnitine (2 g/day) for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 30
Study: 12431966

Group type: EXPERIMENTAL
Intervention: TNP-470 at 60 mg/m² three times per week and paclitaxel at 225 mg/m² administered over 3 hours every 3 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Paclitaxel alone
Number of subjects: 32
Study: 10601925

Group type: EXPERIMENTAL
Intervention: Oral nicardipine (40 mg loading dose, then 20 mg every 2 hours as needed, total 80 mg)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate (6 g bolus followed by 2 to 4 g/h)
Number of subjects: 122
Study: 7677557

Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg/d)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study: 2206826

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg) and nifedipine retard (20 mg) once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atenolol (50 mg once daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fixed combination of atenolol and nifedipine
Number of subjects: 30
Study: 113074

Group type: EXPERIMENTAL
Intervention: 2000 rad in 8 fractions over 10 days with intravenous 5 Fluorouracil (5 F.U.) at a dose of 500 mg daily x 4 days preirradiation and then 12.5 mg/kg daily for 5 days every 28 days for six courses.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Radiotherapy and 5 F.U. in the same schedule as Division I.
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Thiotepa 45 mg intravenously daily for three days and then every 28 days for 6 months.
Number of subjects: 142

Group type: COMPARATOR
Intervention: Quality of life assessment.
Number of subjects: 142
Study: 31791552

Group type: EXPERIMENTAL
Intervention: Ralimetinib (200 mg Q12H) + Gemcitabine (1000 mg/m2 on Days 3 and 10) + Carboplatin (AUC 4 on Day 3)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo + Gemcitabine (1000 mg/m2 on Days 3 and 10) + Carboplatin (AUC 4 on Day 3)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Ralimetinib (200 mg Q12H) + Gemcitabine + Carboplatin
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo + Gemcitabine + Carboplatin
Number of subjects: 118
Study: 31719658

Group type: EXPERIMENTAL
Intervention: Equal ratio ventilation (ERV) of 1:1
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional ratio ventilation (CRV) of 1:2
Number of subjects: 50
Study: 29265873

Group type: EXPERIMENTAL
Intervention: Structured information plus mental contrasting with implementation intentions (MCII)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Unstructured information
Number of subjects: 183

Group type: COMPARATOR
Intervention: Structured information
Number of subjects: 183
Study: 24852938

Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) 5%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) 10%
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) 15%
Number of subjects: 100

Group type: COMPARATOR
Intervention: Synthetic astaxanthin (PC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Palmaria palmata (PP) (0%)
Number of subjects: 100
Study: 22506756

Group type: EXPERIMENTAL
Intervention: Masked words that were semantically related to the target word
Number of subjects: 0

Group type: COMPARATOR
Intervention: Masked words that were semantically unrelated to the target word
Number of subjects: 0
Study: 20691441

Group type: EXPERIMENTAL
Intervention: Fixed-angle volar-locked plates
Number of subjects: 56

Group type: COMPARATOR
Intervention: Manipulation and Kirschner wires
Number of subjects: 56
Study: 19783792

Group type: EXPERIMENTAL
Intervention: Knowledge translation in family nursing
Number of subjects: 0
Study: 16892265

Group type: EXPERIMENTAL
Intervention: Red mixed berry juice (700 mL daily, TEAC: 19.1 mmol/L trolox)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control juice (polyphenol-depleted, TEAC: 2.4 mmol/L trolox)
Number of subjects: 18
Study: 15242204

Group type: EXPERIMENTAL
Intervention: Shaving
Number of subjects: 90

Group type: COMPARATOR
Intervention: Not shaving
Number of subjects: 90
Study: 11380306

Group type: EXPERIMENTAL
Intervention: simple educational intervention
Number of subjects: 114

Group type: COMPARATOR
Intervention: standard care
Number of subjects: 114
Study: 9378844

Group type: EXPERIMENTAL
Intervention: YM90K (36 mg single dose, 24 mg repeated dose over 3 hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YM90K (24 mg repeated doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: YM90K
Number of subjects: 0
Study: 8105723

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 2948280

Group type: EXPERIMENTAL
Intervention: naloxone
Number of subjects: 11

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: sleep loss
Number of subjects: 11
Study: 31116893

Group type: EXPERIMENTAL
Intervention: Nonsupine positioning (NSP)
Number of subjects: 11480

Group type: EXPERIMENTAL
Intervention: Nonsupine positioning (NSP) with direct laryngoscopy
Number of subjects: 11480

Group type: COMPARATOR
Intervention: Supine positioning (SP)
Number of subjects: 11480
Study: 28931500

Group type: EXPERIMENTAL
Intervention: Web-based Cognitive Remediation Therapy (CogRem)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Internet-based control condition (WebInfo)
Number of subjects: 86
Study: 25742919

Group type: EXPERIMENTAL
Intervention: Tirasemtiv 250 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Tirasemtiv 500 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 23361389

Group type: EXPERIMENTAL
Intervention: Referral to and treatment by a trained dietitian
Number of subjects: 146

Group type: COMPARATOR
Intervention: No referral (control group)
Number of subjects: 146
Study: 21654700

Group type: EXPERIMENTAL
Intervention: Richly micronutrient-fortified porridge
Number of subjects: 743

Group type: COMPARATOR
Intervention: Basal micronutrient-fortified porridge
Number of subjects: 743
Study: 18445099

Group type: EXPERIMENTAL
Intervention: Endoscopic-guided nasal anesthesia (EGNA)
Number of subjects: 235

Group type: COMPARATOR
Intervention: Cotton-tipped applicator nasal anesthesia (CTNA)
Number of subjects: 235
Study: 16511336

Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the left temporo-parietal cortex
Number of subjects: 16

Group type: COMPARATOR
Intervention: 1 Hz rTMS over the right temporo-parietal cortex
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham position
Number of subjects: 16
Study: 15276536

Group type: EXPERIMENTAL
Intervention: Leukocyte-depletion (LD) group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 11518200

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (25 g/d providing 7.5 g n-3 LCPUFAs)
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-oleic sunflower oil (25 g/d providing 22 g monounsaturated fatty acids)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Number of subjects: 10

Group type: COMPARATOR
Intervention: High-oleic sunflower oil
Number of subjects: 10
Study: 9545673

Group type: EXPERIMENTAL
Intervention: Cefopzopran (CZOP) 25.0 mg/kg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cefopzopran (CZOP) 20.0 mg/kg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Cefopzopran (CZOP) 18.75 mg/kg
Number of subjects: 2
Study: 8296253

Group type: EXPERIMENTAL
Intervention: Asthma education programme (3 hours)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 3731682

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg po q.i.d. for 2 weeks)
Number of subjects: 9
Study: 27652679

Group type: EXPERIMENTAL
Intervention: Paracetamol (taken regularly or as needed)
Number of subjects: 1365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1365
Study: 26565136

Group type: EXPERIMENTAL
Intervention: Mupirocin/chlorhexidine
Number of subjects: 793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 793
Study: 24917631

Group type: EXPERIMENTAL
Intervention: Standard care plus osteopathic manipulative treatment (SC+OMT)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care only (SCO)
Number of subjects: 52
Study: 22500846

Group type: EXPERIMENTAL
Intervention: Deep breathing intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 23
Study: 20534420

Group type: EXPERIMENTAL
Intervention: CABG + CRT
Number of subjects: 164

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 164
Study: 18445141

Group type: EXPERIMENTAL
Intervention: AGN 201904‐Z (600 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg/day)
Number of subjects: 24
Study: 16324138

Group type: EXPERIMENTAL
Intervention: Computerized anesthesia delivery system (Wand)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Traditional syringe
Number of subjects: 125
Study: 12624625

Group type: EXPERIMENTAL
Intervention: Unfractioned heparin (0.3‐100 IU/min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Substance P (2‐8 pmol/min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Bradykinin (100‐1000 pmol/min)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (2‐8 micro g/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 19
Study: 11576031

Group type: EXPERIMENTAL
Intervention: QI-medications program
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: QI-therapy program
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1356
Study: 9133763

Group type: EXPERIMENTAL
Intervention: ADAS‐Cog subtest scores
Number of subjects: 1648

Group type: EXPERIMENTAL
Intervention: Orientation item of ADAS‐Cog
Number of subjects: 1648
Study: 7699226

Group type: EXPERIMENTAL
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 57

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation
Number of subjects: 57
Study: 3581030

Group type: EXPERIMENTAL
Intervention: CHOP with intermediate dose methotrexate
Number of subjects: 73

Group type: COMPARATOR
Intervention: CHOP without intermediate dose methotrexate
Number of subjects: 73
Study: 28571713

Group type: EXPERIMENTAL
Intervention: Protein-enriched familiar foods and drinks (intervention group, n=67)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard energy and protein rich hospital menu (control group, n=80)
Number of subjects: 147
Study: 27553664

Group type: EXPERIMENTAL
Intervention: MTA cement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Gutta-percha and root canal sealer
Number of subjects: 36
Study: 24341973

Group type: EXPERIMENTAL
Intervention: Observation by an anonymous peer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alone (no observation)
Number of subjects: 0
Study: 24032188

Group type: EXPERIMENTAL
Intervention: Acupuncture at Naoqing Xue (Extra)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (acupuncture at Jiexi, Yanglingquan, and Sanyinjiao)
Number of subjects: 146
Study: 20098350

Group type: EXPERIMENTAL
Intervention: 3-month exercise program (n = 56)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Routine follow-up (n = 49)
Number of subjects: 105
Study: 18410447

Group type: EXPERIMENTAL
Intervention: MyVTD (bortezomib, thalidomide, dexamethasone, and liposomal doxorubicin)
Number of subjects: 70

Group type: COMPARATOR
Intervention: VTD (bortezomib, thalidomide, and dexamethasone)
Number of subjects: 70
Study: 16780650

Group type: EXPERIMENTAL
Intervention: Hydration group (HG) in HOCM (n=14)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-hydration group (NHG) in HOCM (n=13)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Hydration group (HG) in LOCM (n=18)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-hydration group (NHG) in LOCM (n=15)
Number of subjects: 60
Study: 12823235

Group type: EXPERIMENTAL
Intervention: Insulin glargine (30 micro g/ml zinc)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Insulin glargine (80 micro g/ml zinc)
Number of subjects: 204

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 204
Study: 11728289

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 32 mg (with hydrochlorothiazide 12.5 mg if DBP was 90 mmHg or higher at week 8)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil and hydrochlorothiazide
Number of subjects: 304
Study: 8840098

Group type: EXPERIMENTAL
Intervention: aprotinin (200,000 U.I.C. as intravenous bolus injection)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo (10 ml isotonic saline)
Number of subjects: 15
Study: 1538302

Group type: EXPERIMENTAL
Intervention: Cimetidine 5 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine 10 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine 7.5 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cimetidine 15 mg/kg
Number of subjects: 27
Study: 30753623

Group type: EXPERIMENTAL
Intervention: L-histidine injection (0.55 mg in 200 μL 0.75% saline)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: L-histidine injection
Number of subjects: 3
Study: 29193943

Group type: EXPERIMENTAL
Intervention: Local steroids combined with therapeutic exercise at home
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional physical therapy (Control)
Number of subjects: 30
Study: 26427112

Group type: EXPERIMENTAL
Intervention: Standard DCXC therapy (2-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensive DCXC therapy (3-g corbrin capsules, 3 times/d, 3 days before and after angiography)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Basic treatment group
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Standard DCXC therapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intensive DCXC therapy
Number of subjects: 120
Study: 25061764

Group type: EXPERIMENTAL
Intervention: Carbohydrate-electrolyte solution (CES)
Number of subjects: 14

Group type: COMPARATOR
Intervention: No fluid (NF)
Number of subjects: 14
Study: 22693075

Group type: EXPERIMENTAL
Intervention: Dry mouth toothpaste
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fluoride toothpaste (placebo)
Number of subjects: 10
Study: 20386004

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 104
Study: 17157397

Group type: EXPERIMENTAL
Intervention: Thrombolysis for acute myocardial infarction
Number of subjects: 44

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 44
Study: 16354893

Group type: EXPERIMENTAL
Intervention: Atrial overdrive pacing (AOP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (n-CPAP)
Number of subjects: 16
Study: 12108534

Group type: EXPERIMENTAL
Intervention: Educational interventions
Number of subjects: 27
Study: 9472784

Group type: EXPERIMENTAL
Intervention: GR213487B liquid nasal spray (0.4375mg, 4.0mg, or 0.0625mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Lipid alone (control)
Number of subjects: 12